KalVista Pharmaceuticals (KALV) News Today $13.41 +0.45 (+3.47%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$13.41 0.00 (0.00%) As of 08/22/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by BrokeragesAugust 19, 2025 | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 3.7% - Time to Buy?August 16, 2025 | marketbeat.comStocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Rise To 82August 15, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50-Day Moving Average - Time to Sell?August 14, 2025 | marketbeat.comStocks With Rising Relative Strength: KalVista PharmaceuticalsAugust 12, 2025 | msn.comMetagenomi Appoints Laurence Reid, PhD to its Board of DirectorsAugust 11, 2025 | globenewswire.comKalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European UnionAugust 11, 2025 | finance.yahoo.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 | businesswire.comKalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines AgencyJuly 29, 2025 | msn.comKalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)July 27, 2025 | seekingalpha.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 6.5% - Here's WhyJuly 26, 2025 | marketbeat.comKALV - KalVista Pharmaceuticals Inc Key Metrics - MorningstarJuly 25, 2025 | morningstar.comMKalVista Gets CHMP Backing for Ekterly in Hereditary AngioedemaJuly 25, 2025 | marketwatch.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above Fifty Day Moving Average - What's Next?July 25, 2025 | marketbeat.comKalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema AttacksJuly 25, 2025 | businesswire.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Buy" by BrokeragesJuly 25, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for KALV EarningsJuly 16, 2025 | marketbeat.comKalVista Gets U.K. Authorization for Hereditary Angioedema TreatmentJuly 15, 2025 | marketwatch.comKalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaJuly 15, 2025 | finance.yahoo.comKalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaJuly 15, 2025 | businesswire.comEmerald Advisers LLC Has $10.37 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)July 13, 2025 | marketbeat.comKalVista Pharmaceuticals Provides Operational Update and Fiscal Year ...July 12, 2025 | seekingalpha.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Emerald Mutual Fund Advisers TrustJuly 12, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down After Earnings MissJuly 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 32,979 SharesJuly 11, 2025 | insidertrades.comKalVista Pharmaceuticals: EKTERLY Launch and Financial UpdateJuly 10, 2025 | tipranks.comBenjamin L. Palleiko Sells 32,979 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial ResultsJuly 10, 2025 | finanznachrichten.deLeerink Partnrs Has Positive Estimate for KALV Q3 EarningsJuly 10, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for KALV EarningsJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Issues Earnings Results, Misses Expectations By $0.16 EPSJuly 10, 2025 | marketbeat.comKalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial ResultsJuly 10, 2025 | businesswire.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.5% on Analyst UpgradeJuly 9, 2025 | marketbeat.comKalVista's breakthrough drug wins FDA approval after delayJuly 8, 2025 | bizjournals.comFDA approves KalVista’s Ekterly for hereditary angioedemaJuly 8, 2025 | msn.comStocks With Rising Relative Price Strength: KalVista PharmaceuticalsJuly 8, 2025 | msn.comUS FDA approves KalVista's oral swelling disorder drug, shares riseJuly 8, 2025 | msn.comJMP Securities Issues Positive Forecast for KalVista Pharmaceuticals (NASDAQ:KALV) Stock PriceJuly 8, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $27.00July 8, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Sets New 52-Week High on Analyst UpgradeJuly 8, 2025 | marketbeat.comLeerink Partners Increases KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00July 7, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Here's What HappenedJuly 7, 2025 | marketbeat.comKalVista stock soars after FDA approves first oral HAE treatmentJuly 7, 2025 | investing.comKalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema DrugJuly 7, 2025 | marketwatch.comUS FDA approves KalVista Pharma's swelling disorder drug, shares riseJuly 7, 2025 | msn.comUS FDA approves KalVista Pharma's swelling disorder drugJuly 7, 2025 | reuters.comKalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary AngioedemaJuly 7, 2025 | businesswire.comKalVista Pharmaceuticals (KALV) Expected to Announce Quarterly Earnings on ThursdayJuly 3, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (KALV) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼1.000.71▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼24▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RXRX News CPRX News KNSA News OGN News ALVO News CNTA News IBRX News TARS News OCUL News AGIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access